Photo from ESMO/LinkedIn
Jun 13, 2024, 07:54
Connect to the ESMO Virtual Plenary to stay up to date with the latest in immunotherapy
ESMO shared on LinkedIn:
“What are the early safety and activity profiles of a first-in-class PD-1/IL-2 bispecific in patients with solid tumors?
Connect today to the ESMO Virtual Plenary with international experts in oncology to stay up to date with the latest in immunotherapy.”
Source: ESMO/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 22, 2024, 08:02
Oct 22, 2024, 07:20
Oct 22, 2024, 06:30
Oct 22, 2024, 06:13
Oct 22, 2024, 03:40
Oct 22, 2024, 00:56
Oct 22, 2024, 00:49
Oct 22, 2024, 00:40
Oct 22, 2024, 00:34